Zoetis Inc. (NYSE:ZTS) Declares Quarterly Dividend of $0.53

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Thursday, February 5th. Investors of record on Monday, April 20th will be paid a dividend of 0.53 per share on Tuesday, June 2nd. This represents a c) annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th.

Zoetis has raised its dividend payment by an average of 0.2%annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Zoetis has a payout ratio of 31.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Zoetis to earn $6.75 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 31.4%.

Zoetis Stock Up 1.4%

Shares of ZTS traded up $1.78 during midday trading on Friday, hitting $128.51. The stock had a trading volume of 1,530,459 shares, compared to its average volume of 4,455,860. The firm has a market cap of $56.63 billion, a price-to-earnings ratio of 21.63, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. The company has a 50 day simple moving average of $123.97 and a two-hundred day simple moving average of $136.55. Zoetis has a twelve month low of $115.25 and a twelve month high of $177.00. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 EPS. On average, analysts anticipate that Zoetis will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Bank of America cut Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target for the company. in a report on Monday, December 15th. JPMorgan Chase & Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.